Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. MorphoSys AG
  6. Company
    MOR   DE0006632003

MORPHOSYS AG

(MOR)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 07/28 03:59:57 pm
45.64 EUR   +0.73%
04:14pMORPHOSYS : Reports Second Quarter and First Half 2021 Results
PU
04:04pPRESS RELEASE : MorphoSys AG Reports Second -3-
DJ
04:04pPRESS RELEASE : MorphoSys AG Reports Second -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo MorphoSys AG
MorphoSys AG is one of the world's leading groups of biotechnology. Net sales break down by activity as follows:

- development of antibody for therapeutic applications in partnership with pharmaceutical and biotechnology companies (52.2%): for treating rheumatoid arthritis, cancers and infectious diseases;

- proprietary development of therapeutic antibodies and peptides (47.8%).

At the end of 2019, the MorphoSys AG held a portfolio of 28 products in clinical development including 5 in phase III, 13 in phase II and 10 in phase I, and 25 products in preclinical development phase.

Net sales break down geographically as follows: Germany (0.2%), Europe and Asia (54.8%) and North America (45%).

Number of employees : 615 people.
Sales per Business
20192020Delta
Proprietary Development34.2947.8%278.6385% +712.66%
Partnered Discovery37.4752.2%49.0715% +30.96%
EUR in Million
Sales per region
20192020Delta
United States and Canada32.2945%319.0697.4% +888.16%
Europe and Asia39.3254.8%8.642.6% -78.03%
Germany0.150.2%---
EUR in Million
Managers
Name Title Age Since
Jean-Paul Kress, Dr. CEO & Chairman-Management Board 54 2019
Sung H. Lee Chief Financial Officer 49 2021
Malte Peters, Dr. Chief Research & Development Officer 57 2020
Roland Wandeler, Dr. Chief Operating Officer 47 -
Armin Weidmann, Dr. Head-Compliance & Quality Assurance - -
Marc Cluzel, Dr. Chairman-Supervisory Board 65 2018
Wendy S. Johnson Member-Supervisory Board 68 2015
Krisja Vermeylen Member-Supervisory Board 57 2017
Julia Neugebauer, Dr. Senior Director-Investor Relations - 2020
Barbara Krebs-Pohl, Dr. Head-Business Development & Portfolio Management - -
Members of the board
Name Title Age Since
Marc Cluzel, Dr. Chairman-Supervisory Board 65 2018
Wendy S. Johnson Member-Supervisory Board 68 2015
Krisja Vermeylen Member-Supervisory Board 57 2017
Michael Brosnan Member-Supervisory Board 65 2018
George S. Golumbeski, Dr. Deputy Chairman-Supervisory Board 62 -
Sharon Evelyn Curran Member-Supervisory Board 51 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 32,892,540 32,761,126 99.6% 131,414 0.4% 99.6%
Shareholders
NameEquities%
Baillie Gifford & Co. 1,588,526 4.83%
Invesco Advisers, Inc. 1,308,889 3.98%
T. Rowe Price International Ltd. 1,204,911 3.66%
Artisan Partners LP 1,108,762 3.37%
The Vanguard Group, Inc. 886,414 2.70%
Lyxor International Asset Management SAS 844,260 2.57%
Norges Bank Investment Management 835,219 2.54%
Flossbach von Storch AG 628,551 1.91%
Fidelity Management & Research Co. LLC 575,188 1.75%
BlackRock Asset Management Deutschland AG 539,786 1.64%
Company contact information
MorphoSys AG
Semmelweisstrasse 7
Planegg, Bayern (Bavaria) 82152

Phone : +49.89.89927.0
Fax : +49.89.89927.222
Web : http://www.morphosys.de
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
MORPHOSYS AG-51.71%1 828
MODERNA, INC.214.44%131 902
LONZA GROUP AG20.01%55 520
IQVIA HOLDINGS INC.35.73%46 608
CELLTRION, INC.-26.60%31 131
SEAGEN INC.-17.54%26 209
PHARMARON BEIJING CO., LTD.54.90%21 498
CUREVAC N.V.-35.40%21 497
ALNYLAM PHARMACEUTICALS, INC.35.87%20 757
HANGZHOU TIGERMED CONSULTING CO., LTD-4.58%20 084
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.57.19%19 737
BIO-TECHNE CORPORATION49.14%18 419
INCYTE CORPORATION-11.12%16 789
PPD, INC.34.28%16 137
NOVAVAX, INC.60.53%13 261
ICON PUBLIC LIMITED COMPANY14.71%11 845
QIAGEN N.V.-2.21%11 796
PRA HEALTH SCIENCES, INC.0.00%10 965
INTELLIA THERAPEUTICS, INC.143.33%9 617
CRISPR THERAPEUTICS AG-23.30%9 409
SYNEOS HEALTH, INC.28.96%9 078